The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
Exactly Ciaskin - stage 3/4 unresectable. Superb.
Violin - hope that's a cheer up ! Worth the wait ? ATB
I liked this re. SCOPE : "Based upon the first 13 patients there is a greater than 90% probability that the second phase will also be successful."
And iSCIB1+ re. MHRA : "Management do not see any potential issue with this regulatory request having previously completed identical studies with SCIB1".
Topped by Prof. Lindy commenting : "we now anticipate the iSCIB1+ cohort to commence in Q1 2024. We look forward to providing further updates on our progress given the extremely positive results to date."
That's 'EXTREMELY POSITIVE' Guys !
Just to add, a positive well written RNS this time. GLA
Bojo agreed. GLA
Johnny thanks for that from MM and Violin for the full script - ery interesting . . . .
To see Mmum post this, as Johnny quoted, "Right now, I really do feel normal again" is touching if not bl**dy wonderful (ModiFy or not).
And "Oh and for the record, I feel indestructible". Yes !!!!
Come on Mmum and come on Scancell
https://community.macmillan.org.uk/cancer-blogs/b/kidney-not/posts/two-years-on
Cleaner your 11.13 yesterday. To repeat your link https://www.ksat.com/news/local/2023/10/02/new-type-of-covid-vaccine-showing-promise-at-texas-biomed
I see the 'ksat' report was dated Oct 1st and I'm not sure if it's been posted here before. But anyway, IMHO that's BRILLIANT news.
I had wondered if Texas BioMed were just casting an eye over the Covidity files but it seems clear from 'ksat' that they are actually working with it.
" “It’s a big deal. We have inquiries from all over the world. Actually, we had from South Korea, India, France and UK,” Kulkarni said.The research on the DNA COVID vaccine is being done with a company in the UK, and it’s looking very promising. Kulkarni and his team just finished the phase using mice, and he said it was almost 100% effective. There were also no serious side effects. . . .
. . . The research team is now waiting for official approval to move into primate studies, hopefully followed by FDA human clinical trials."
This rather passed me by. Whilst there's not been an RNS of a deal with Texas BioMed some arrangement must be in place if they are working with our Baby!
Maybe we can expect an RNS on this subject at some point AND even better, some dosh in the coffers. GLA
Cleaner, thanks for posting the details of these tie-ups.
So J V-T has signed up for the mRNA beanfeast - that's a little disappointing on the face of it BUT there's the consolation FWIW that he has some insights into the progress with DNA vaccines in Nottingham !
C11 - I agree - "That 10 year partnership won’t simply evaporate" !
Another BUT - "with totally compelling trial data, it isn’t impossible to challenge the heavyweight’s of industry". Good post.
Roll on the day . . . .
The FDA and Moderna seem to have a cosy relationship - lax rules and a revolving door ? Moderna also seem to have 'inside track' in matters UK.
https://www.bmj.com/content/383/bmj.p2486
Chester 15.01 I agree. We can hope for something new in an RNS even up to the Wednesday morning but otherwise, it's in the detail of what Prof. Lindy says and the way that she says it that usually proves interesting. It will be an interesting week one way or another.
Jambo - "a steady increase in the SP leading up to the AGM" - maybe or maybe not Jambo but there is 3 days to go . . .
Violin - yours 12th November - you self-identify "As chief moaner...." Yes I have to agree with your judgement. Well done !
You have reached the worst of despair in your 13.57 today - this is bullocks Violin - "the AGM will be as follows, and every LTH investor knows this". No we bl**dy don't!
What you have done in inventing that conversation is negative, scurrilous and totally unnecessary - I could hardly believe my eyes . . . I think our CEO would be disappointed though God knows, she has enough sense to ignore such carp.
FGS - if you feel that way - please sell. I understand where you are coming from but really, I was very disappointed to read that. The Scancell AGM always brings some excitement even if in only routine updates.
Wait and see eh? Patience . . . . .
Ciaskin that's right of course - 'RIP personalised medicines' was just one side of a discussion. BUT, for me, it's interesting that some at least are beginning to twig the point, that 'personalised medicines' may NOT be the way forward and that other possibilities exist. GLA
Cleaner that was a great 'Clatterbridge' find yesterday and thanks for that.
Regarding the original point of the thread, we can rely on Scancell's reply to Chester that he kindly published on Nov 20th 13.07.
Subject: Re: SCIB1 Charts September/ November - Answer from Scancell regarding the difference in the two Swimmer Line Charts as presented as Abstracts at a conference in September and the one presented on the 9th November :-
"We have two cohorts in the SCOPE study one is SCIB1 with @CTLA4 and @PD1 and this is the cohort that have an 82% response rate and are doing amazingly well. The second cohort is SCIB1 with just @PD1. This cohort has a 67% response rate but is difficult to recruit too as most patients get the double checkpoints. We only have three patients in this cohort. The poster reflects both groups and the abstracts are submitted well before the meetings. The SMR meeting was a late breaking session so the abstracts were submitted nearer the meeting although the meeting was after the CIMT meeting. So the simple answer is timing and cohorts but the bottom line is the double checkpoint group plus SCIB1 is doing very well".
Kind regards, Prof Lindy Durrant CEO"
I thought I'd repeat in the hope that Burble can comment on that if he's around.
Thanks Chester.
Thank you Botski - that's brilliant !
Maybe we'll get some updates before the AGM next Wednesday but this week is likely to be quiet ? Perhaps the lull before ?
(RR - great to see Prof Christian Ottersmeier in Moditope action last week - I agree the more the word is spread, the better !! )
Maybe Violin but at my age the audience all looked like students LOL. I liked the London Buses analogy but maybe you wait for one Scancell bus and 5 come along. Time will tell . . .
Never mind - to spread the message is a good idea and Prof. Ottensmeier obviously enough, has faith. So should we. GN.
Marcus on PoG has posted these X links showing Prof. Christian Ottensmeier giving a keynote Moditope address at Liverpool Head and Neck Centre.
Sponsors include Scancell and Merck
https://twitter.com/livHeadandNeck/status/1725482027657330959?
https://twitter.com/livHeadandNeck/status/1725475782145765427?
https://twitter.com/livHeadandNeck/status/1725449472543457668?
Ray I agree with your suggestion that there could be an "inevitable spread from all connected to the Scope trial. This includes patients and their friends and relatives, hospital staff and anyone else connected to the trial".
I'd call it a 'buzz' but it's not 'insider trading'.
Another factor might be previous holders deciding the timing is right to return or hold a little more.
Not a great deal going on but it's always good to see blue and 7% is not to be sneezed at ! Nice weekend all . . .
V re. 14.24 - I can't and I'm not arguing that. GN
Violin - 'insider dealing' is a serious offence so IMO it's not good to suggest it's going on. As I suggested, a little rise is nice but 'bigger all' in the scale of things.
Maybe a few at the Conferences have decided on a punt on Scancell but we don't know at all do we ? Whether it's that or the direction of the wind in Timbuktu?
Yes I'm still in Thailand, give it a go - 1 day in BKK, 1 day in Pattaya, and the rest of your time somewhere nice LOL Try Chantaburi - I'll buy you a pint. ATB
C11 - Ha ha !
Strewth Violin - just noticed 'no longer the tight ship'. Not sure that Scancell would be delighted to see that and sorry but one makes a lot of assumptions to reach that conclusion.
But UP is better than DOWN. That's all we know. ATB